Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I–III breast cancer: ER+/PR+, HER2- vs. triple-negative

Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes

(2017) Gary H. Lyman   Journal of the National Comprehensive Cancer Network

Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy

(2015) Jia-qi Yuan et al.   BREAST CANCER RESEARCH AND TREATMENT

A review of relative dose intensity and survival in patients with metastatic solid tumors

(2015) Laura J. Havrilesky et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices

(2015) Neelima Denduluri et al.   Journal of the National Comprehensive Cancer Network

The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes

(2015) Peter C Austin et al.   STATISTICAL METHODS IN MEDICAL RESEARCH

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy

(2014) Hee Jin Lee et al.   ANNALS OF SURGICAL ONCOLOGY

Molecular markers for breast cancer diagnosis, prognosis and targeted therapy

(2014) Julie E. Lang et al.   JOURNAL OF SURGICAL ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting

(2013) Gary H. Lyman et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy

(2012) Hyeong-Gon Moon et al.   BREAST CANCER RESEARCH AND TREATMENT

Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

(2012) Derek Weycker et al.   BREAST CANCER RESEARCH AND TREATMENT

Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting

(2012) Lisa M. McShane et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

(2011) Sibylle Loibl et al.   BMC CANCER

Weight Trimming and Propensity Score Weighting

(2011) Brian K. Lee et al.   PLoS One

Use of Stabilized Inverse Propensity Scores as Weights to Directly Estimate Relative Risk and Its Confidence Intervals

(2009) Stanley Xu et al.   VALUE IN HEALTH

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

(2008) Isabel Chirivella et al.   BREAST CANCER RESEARCH AND TREATMENT